Synthesis and Pharmacological Characterization of <i>C</i>4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1<i>R</i>,2<i>S</i>,4<i>R</i>,5<i>R</i>,6<i>R</i>)-2-Amino-4-(1<i>H</i>-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu<sub>2</sub> Receptor Agonist
作者:James A. Monn、Lourdes Prieto、Lorena Taboada、Junliang Hao、Matthew R. Reinhard、Steven S. Henry、Christopher D. Beadle、Lesley Walton、Teresa Man、Helene Rudyk、Barry Clark、David Tupper、S. Richard Baker、Carlos Lamas、Carlos Montero、Alicia Marcos、Jaime Blanco、Mark Bures、David K. Clawson、Shane Atwell、Frances Lu、Jing Wang、Marijane Russell、Beverly A. Heinz、Xushan Wang、Joan H. Carter、Brian G. Getman、John T. Catlow、Steven Swanson、Bryan G. Johnson、David B. Shaw、David L. McKinzie
DOI:10.1021/acs.jmedchem.5b01124
日期:2015.9.24
Identification of orthosteric mGlu(2/3) receptor agonists capable of discriminating between individual mGlu(2) and mGlu(3) subtypes has been highly challenging owing to the glutamate-site sequence homology between these proteins. Herein we detail the preparation and characterization of a series of molecules related to (1S,2S,5R,65)-2-aminobicyclo [3.1.0]hexane-2,6-dicarboxylate 1 (LY354740) bearing C4-thiotriazole substituents. On the basis of second messenger responses in cells expressing other recombinant human mGlu(2/3) subtypes, a number of high potency and efficacy mGlu(2) receptor agonists exhibiting low potency mGlu(3) partial agonist/antagonist activity were identified. From this, (1R,2S,4R,512,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicydo[3.1.0]hexane-2,6-dicarboxylic acid 14a (LY2812223) was further characterized. Cocrystallization of 14a with the amino terminal domains of hmGlu(2) and hmGlu(3) combined with site-directed mutation studies has clarified the underlying molecular basis of this unique pharmacology. Evaluation of 14a in a rat model responsive to mGlu(2) receptor activation coupled with a measure of central drug disposition provides evidence that this molecule engages and activates central mGlu(2) receptors in vivo.